For MS the number of treatments that made it to the clinic is depressingly low, however (a) that's changed recently, and (b) in this case it's a new pathway. So

For MS the number of treatments that made it to the clinic is depressingly low, however (a) that's changed recently, and (b) in this case it's a new pathway. So maybe this is interesting.